Cargando…

Immunochemotherapy - A Missed Opportunity for Metastasized Malignant Melanoma? Reporting a Therapeutic Success with Checkpoint Inhibitor Rechallenge after Cytotoxic Immuno-Priming in a Heavily Pretreated Patient

Treatment of metastasized malignant melanoma still has very limited therapeutic options. After exhaustion of immuno-checkpoint inhibition (ICI) and potentially targeted therapy, no promising alternatives are currently available. We report on an 83-year-old patient suffering from disseminated metasta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kiderlen, Til R., Delmastro, Nicola, Jobst, Friedemann, de Wit, Maike
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Single Case
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459574/ https://www.ncbi.nlm.nih.gov/pubmed/36158860 http://dx.doi.org/10.1159/000525153

Ejemplares similares

Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature
por: Di Lorenzo, Giuseppe, et al.
Publicado: (2016)

Herpes Zoster Vaccination Rates in Hematological and Oncological Patients—Stock Taking 2 Years after Market Approval
por: Kiderlen, Til Ramón, et al.
Publicado: (2022)

Essential barriers and considerations for the implementation of electronic patient-reported outcome (ePRO) measures in oncological practice: contextualizing the results of a feasibility study with existing literature
por: Kiderlen, Til Ramón, et al.
Publicado: (2022)

Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade–resistant Melanoma for Anti-PD-L1 Rechallenge
por: van der Westhuizen, Andre, et al.
Publicado: (2022)

Bell's palsy during rechallenge of immune checkpoint inhibitor
por: Takemura, Kohji, et al.
Publicado: (2023)

Recurrence of Hypophysitis After Immune Checkpoint Inhibitor Rechallenge
por: Park, Benjamin C, et al.
Publicado: (2022)

Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2018)

Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
por: Bylsma, Sophia, et al.
Publicado: (2022)

Rechallenge in Immune Checkpoint Inhibitors Associated Renal Tubular Acidosis
por: Shah, Chintan V., et al.
Publicado: (2023)

Basal Cell Carcinoma on the Sole: An Easily Missed Cancer
por: Hone, Natalie L., et al.
Publicado: (2016)

Low Back Pain in Hidradenitis Suppurativa: A Diagnosis Not to Miss!
por: Schnebert, Benjamin, et al.
Publicado: (2018)

Stereotactic Body Radiation Therapy for Patients with Heavily Pretreated Liver Metastases and Liver Tumors
por: Lanciano, Rachelle, et al.
Publicado: (2012)

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2022)

The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
por: Oriol, Albert, et al.
Publicado: (2021)

Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma
por: Gil-Sierra, Manuel David, et al.
Publicado: (2022)

Diffuse Metastatic Melanoma in the GI Lumen Following Immune Checkpoint Inhibitor Colitis Treatment
por: Sperling, Gabriel, et al.
Publicado: (2022)

Novel galenic formulations for delivering immunochemotherapies: kill intelligently, remove the checkpoint and let the T cells in!
por: Kepp, Oliver, et al.
Publicado: (2020)

The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge—A Systematic Review
por: Perdyan, Adrian, et al.
Publicado: (2023)

Successful Treatment of an Immune-Mediated Colitis Induced by Checkpoint Inhibitor Therapy in a Patient with Advanced Melanoma
por: Paparoupa, Maria, et al.
Publicado: (2020)

Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer
por: Lee, Jin Sun, et al.
Publicado: (2021)

Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas
por: Olsen, Ingrid Holst, et al.
Publicado: (2014)

A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide
por: Cerchione, Claudio, et al.
Publicado: (2017)

Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients
por: Delforge, Michel, et al.
Publicado: (2022)

Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report
por: Dias e Silva, Douglas, et al.
Publicado: (2023)

Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non‐small cell lung cancer
por: Takahara, Yutaka, et al.
Publicado: (2022)

Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis
por: Gao, Wen, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions
por: Sammarco, Enrico, et al.
Publicado: (2023)

Current trends of anticancer immunochemotherapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Melanoma: BRAFi Rechallenge
por: Kosmidis, Christoforos S., et al.
Publicado: (2023)

Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Pretreatment CT Texture Parameters as Predictive Biomarkers of Progression-Free Survival in Follicular Lymphoma Treated with Immunochemotherapy and Rituximab Maintenance
por: Durot, Carole, et al.
Publicado: (2023)

Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events
por: Isik, Busra, et al.
Publicado: (2021)

Successful immune checkpoint inhibitor rechallenge after immune-related pericarditis: Clinical case series
por: Chye, Adrian M., et al.
Publicado: (2022)

Value of troponin T versus I in the diagnosis of immune checkpoint inhibitor‐related myocarditis and myositis: rechallenge?
por: Rossi, Valentina A., et al.
Publicado: (2023)

A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects
por: Utsunomiya, Akira, et al.
Publicado: (2018)

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer.
por: Smit, E. F., et al.
Publicado: (1998)

Efficacy of Fulvestrant in Heavily Pretreated Postmenopausal Women with Advanced Breast Cancer: A Preliminary Report
por: Yoo, Changhoon, et al.
Publicado: (2011)

Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report
por: Krawczyk, Katarzyna, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_irhc6501rp8h221dtir8skqu92